DEERFIELD, Ill.--(BUSINESS WIRE)--Option Care Enterprises, Inc., a leading national provider of home and alternate treatment site infusion services, has been selected as the contracted provider of RELiZORB™ (immobilized lipase), which helps patients with complex medical conditions digest and absorb the “essential fats” they receive through enteral nutrition (tube feeding). Relizorb is manufactured by Alcresta Pharmaceuticals, Inc.
Recently approved as a de novo device by the U.S. Food and Drug Administration, Relizorb is a first-of-its-kind digestive enzyme cartridge designed to mimic the normal pancreatic function by breaking down fats in enteral tube feeding formula. By breaking down these fats prior to ingestion, Relizorb allows for the delivery of increased absorbable calories from fatty acids and monoglycerides to adults who are partially or completely unable to breakdown and absorb fats. Relizorb has been shown to break down 90 percent of fats in most enteral feeding tube formulas, including the most difficult to breakdown long-chain polyunsaturated fatty acids, which are critical for growth and development.
“We’re so pleased to be chosen to provide such an innovative product, which we believe can improve the quality of life for patients in need of nutrition therapy,” said Kimberly Petruccelli, PharmD, MBA, clinical program manager of specialty infusion programs for Option Care. “Our registered dietitians have extensive experience and expertise caring for patients in need of complex therapies, including enteral nutrition, and can ensure they receive the highest level of care.”
Option Care was selected to provide and support the administration of Relizorb due to its ability to deliver individualized treatment through its Nutrition Support Program, which follows a multidisciplinary patient care team approach and includes a registered dietitian at every one of its branches. One of the nation’s largest providers of home and alternate treatment site infusion services, Option Care has the capability to provide safe, effective nutrition care for patients nationwide through its 92 infusion pharmacies.
“Option Care will play a key role in bringing Relizorb to patients through its dietitian-led patient care teams,” said John Tucker, chief executive officer of Alcresta. “The company is an ideal partner because of its proven track record of providing high-quality care and its national presence with patients, payers and providers.”
“Option Care is honored to have been selected by Alcresta as the Relizorb provider of choice, and we’re committed to making this product an accessible option for patients, providers and payers,” said Matthew Deans, vice president of business development for Option Care. “We believe that in developing customized clinical management programs in partnership with biopharmaceutical manufacturers, we can increase patient access to novel therapies. It’s our priority that patients receive the full therapeutic benefit of the treatment, which can lead to increased satisfaction, improved outcomes and lower total cost of care.”
About Option Care
Option Care Enterprises, Inc., offers clinical care provided by specially trained infusion nurses, pharmacists and dietitians who treat patients with a wide range of acute, chronic and rare conditions. As one of the nation’s largest providers of home and alternate treatment site infusion services, Option Care has 92 infusion pharmacies and 110 alternate treatment sites across the country. Learn more at www.OptionCare.com.